The Role of Circulating Tumor DNA in Surgical Management of Pancreatic Cancer
Both preoperative and postoperative ctDNA are significant negative prognostic markers in patients with PDAC undergoing surgery. In subgroup analysis, ctDNA maintained its prognostic value in both the upfront resection and neoadjuvant treatment groups. Monitoring ctDNA can help personalize treatment, specifically in the selection of patients for neoadjuvant, surgical, and adjuvant therapies.
Authors
- Christoph Berchtold
- Vera Oliveira
- Marisa Aral (ORCID: https://orcid.org/0000-0001-8522-2064)
- Ana Alagoa João (ORCID: https://orcid.org/0000-0002-6261-6885)
- Ela Hutten
- Arianeb Mehrabi (ORCID: https://orcid.org/0000-0003-2843-1390)
- Gil Gonçalves
- José Filipe Cunha
- Markus W. Büchler
- Marta Sousa
- Miguel F. Borges
- Filipe C. Borges
- Peter Bailey
- Mafalda S. Pinto
Institutions
- Champalimaud Foundation (PT)
- University of Lisbon (PT)
Publication Details
- Journal
- Annals of Surgery
- Published
- 2026-02-16
- DOI
- https://doi.org/10.1097/sla.0000000000007036
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00